Loading
Myomo, Inc. is a medical technology company specializing in wearable robotics. The company engineers and manufactures advanced myoelectric orthoses, primarily for individuals in the United States who experience neuromuscular impairments. Its flagship product, MyoPro, is an upper-limb brace that utilizes muscle signals to assist patients with weak or paralyzed arms, thereby enhancing their ability to perform daily activities. These devices aim to restore function for both adult and adolescent patients suffering from various neurological conditions, including stroke, spinal cord injury, traumatic brain injury, and brachial plexus injuries. Myomo distributes its innovative solutions through a network that includes orthotics and prosthetics providers, rehabilitation hospitals, the Veterans Health Administration, and additional distributors. Established in 2004, Myomo, Inc. maintains its corporate headquarters in Boston, Massachusetts.
Regular session
$1.395
−$0.055 · -3.79%
Regular session · ET · Market data may be delayed.
Myomo, Inc. is a medical technology company specializing in wearable robotics. The company engineers and manufactures advanced myoelectric orthoses, primarily for individuals in the United States who experience neuromuscular impairments. Its flagship product, MyoPro, is an upper-limb brace that utilizes muscle signals to assist patients with weak or paralyzed arms, thereby enhancing their ability to perform daily activities. These devices aim to restore function for both adult and adolescent patients suffering from various neurological conditions, including stroke, spinal cord injury, traumatic brain injury, and brachial plexus injuries. Myomo distributes its innovative solutions through a network that includes orthotics and prosthetics providers, rehabilitation hospitals, the Veterans Health Administration, and additional distributors. Established in 2004, Myomo, Inc. maintains its corporate headquarters in Boston, Massachusetts.
Day range
Current $1.395
52-week range
Current $1.395
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
72
Undervalued
Sentiment
53
Mixed
Risk
76
High Risk
Momentum
52
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Myomo, Inc. is a medical technology company specializing in wearable robotics. The company engineers and manufactures advanced myoelectric orthoses, primarily for individuals in the United States who experience neuromuscular impairments. Its flagship product, MyoPro, is an upper-limb brace that utilizes muscle signals to assist patients with weak or paralyzed arms, thereby enhancing their ability to perform daily activities. These devices aim to restore function for both adult and adolescent patients suffering from various neurological conditions, including stroke, spinal cord injury, traumatic brain injury, and brachial plexus injuries. Myomo distributes its innovative solutions through a network that includes orthotics and prosthetics providers, rehabilitation hospitals, the Veterans Health Administration, and additional distributors. Established in 2004, Myomo, Inc. maintains its corporate headquarters in Boston, Massachusetts.
Day range
Current $1.395
52-week range
Current $1.395
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 40.93M USD | 32.55M USD | 19.24M USD | 15.56M USD | 13.86M USD |
| Cost of goods sold | 14.04M USD | 9.37M USD | 6.06M USD | 5.3M USD | 3.54M USD |
| Gross profit | 26.89M USD | 23.19M USD | 13.18M USD | 10.25M USD | 10.31M USD |
| Research and development | 6.94M USD | 4.77M USD | 2.64M USD | 2.48M USD | 2.56M USD |
| Selling, general, and administrative | 34.35M USD | 24.62M USD | 18.78M USD | 18.44M USD | 18.02M USD |
| Operating expenses | 41.29M USD | 29.39M USD | 21.41M USD | 20.93M USD | 20.58M USD |
| Interest income | 476.97K USD | 388.59K USD | 410.27K USD | 88.73K USD | 1.61K USD |
| Interest expense | 927.8K USD | — | — | — | — |
| Depreciation and amortization | 1.98M USD | 776.97K USD | 517.68K USD | 542.63K USD | 335.96K USD |
| Operating income | −14.4M USD | −6.21M USD | −8.23M USD | −10.67M USD | −10.27M USD |
| Net income | −15.57M USD | −6.18M USD | −8.15M USD | −10.72M USD | −10.37M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$3.45
147.31% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jan 31, 2020 | 1:30 | — | — |
Effective Jan 31, 2020
1:30
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
